Nanna Svartz väg 6A
Solna 17165
Sweden
46 8 52 48 60 70
https://www.karolinskadevelopment.com
Settore/i:
Settore:
Impiegati a tempo pieno: 8
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Viktor Drvota M.D., Ph.D. | Chief Executive Officer | 4,73M | N/D | 1965 |
Mr. Hans Christopher Toll | Chief Financial Officer | N/D | N/D | 1968 |
Mr. Per Aniansson | Investment Director | N/D | N/D | 1966 |
Ms. Eva Montgomerie | Head of Accounting | N/D | N/D | 1958 |
Dr. John Öhd M.D., Ph.D. | Chief Scientific Officer & Venture Partner | N/D | N/D | 1971 |
Mr. Johan Dighed | Chief Legal Officer & Deputy CEO | N/D | N/D | 1973 |
Mr. Yan Cheng | President of Asia | N/D | N/D | 1985 |
Prof. Hans Wigzell M.D., Ph.D. | Senior Strategic Advisor | 500k | N/D | 1938 |
Mr. Tse Ping | Senior Strategic Advisor | N/D | N/D | 1952 |
Ms. Linda Spahiu | Investment Manager | N/D | N/D | 1985 |
Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.
L'ISS Governance QualityScore di Karolinska Development AB (publ) al 1 aprile 2024 è 4. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 5; diritti degli azionisti: 7; retribuzione: 4.